Pharma major Lupin targets $1 bn revenue from inorganic growth by FY18 #pharma #world

Posted On Dec 1 2017 by

#lupin pharma # Pharma major Lupin targets $1 bn revenue from inorganic growth by FY18 Sohini Das | Ahmedabad Jan 19, 2016 10:01 AM IST Looking to add $1 billion in revenues from inorganic growth to reach its target turnover of $5 billion by 2018, pharma giant Lupin, which is currently worth $2 billion, says it is open to late stage speciality assets. Lupin s chief financial officer Ramesh Swaminathan told Business Standard that while $200-300 million per acquisition is a sweet spot for the company historically, it does not mean that the company won t look at bigger acquisitions. …


Pharma major Lupin targets $1 bn revenue from inorganic growth by FY18 #generic #pharmaceuticals

Posted On Aug 8 2017 by

#lupin pharma # Pharma major Lupin targets $1 bn revenue from inorganic growth by FY18 Sohini Das | Ahmedabad Jan 19, 2016 10:01 AM IST Looking to add $1 billion in revenues from inorganic growth to reach its target turnover of $5 billion by 2018, pharma giant Lupin, which is currently worth $2 billion, says it is open to late stage speciality assets. Lupin s chief financial officer Ramesh Swaminathan told Business Standard that while $200-300 million per acquisition is a sweet spot for the company historically, it does not mean that the company won t look at bigger acquisitions. …


Pharma major Lupin targets $1 bn revenue from inorganic growth by FY18 #gland #pharma

Posted On Jul 4 2017 by

#lupin pharma # Pharma major Lupin targets $1 bn revenue from inorganic growth by FY18 Sohini Das | Ahmedabad Jan 19, 2016 10:01 AM IST Looking to add $1 billion in revenues from inorganic growth to reach its target turnover of $5 billion by 2018, pharma giant Lupin, which is currently worth $2 billion, says it is open to late stage speciality assets. Lupin s chief financial officer Ramesh Swaminathan told Business Standard that while $200-300 million per acquisition is a sweet spot for the company historically, it does not mean that the company won t look at bigger acquisitions. …


Pharma major Lupin targets $1 bn revenue from inorganic growth by FY18 #acceleron #pharma

Posted On May 15 2017 by

#lupin pharma # Pharma major Lupin targets $1 bn revenue from inorganic growth by FY18 Sohini Das | Ahmedabad Jan 19, 2016 10:01 AM IST Looking to add $1 billion in revenues from inorganic growth to reach its target turnover of $5 billion by 2018, pharma giant Lupin, which is currently worth $2 billion, says it is open to late stage speciality assets. Lupin s chief financial officer Ramesh Swaminathan told Business Standard that while $200-300 million per acquisition is a sweet spot for the company historically, it does not mean that the company won t look at bigger acquisitions. …


Pharma major Lupin targets $1 bn revenue from inorganic growth by FY18 #msd #pharma

Posted On Mar 18 2017 by

#lupin pharma # Pharma major Lupin targets $1 bn revenue from inorganic growth by FY18 Sohini Das | Ahmedabad Jan 19, 2016 10:01 AM IST Looking to add $1 billion in revenues from inorganic growth to reach its target turnover of $5 billion by 2018, pharma giant Lupin, which is currently worth $2 billion, says it is open to late stage speciality assets. Lupin s chief financial officer Ramesh Swaminathan told Business Standard that while $200-300 million per acquisition is a sweet spot for the company historically, it does not mean that the company won t look at bigger acquisitions. …


Pharma major Lupin targets $1 bn revenue from inorganic growth by FY18 #pharma #brands

Posted On Feb 12 2017 by

#lupin pharma # Pharma major Lupin targets $1 bn revenue from inorganic growth by FY18 Sohini Das | Ahmedabad Jan 19, 2016 10:01 AM IST Looking to add $1 billion in revenues from inorganic growth to reach its target turnover of $5 billion by 2018, pharma giant Lupin, which is currently worth $2 billion, says it is open to late stage speciality assets. Lupin s chief financial officer Ramesh Swaminathan told Business Standard that while $200-300 million per acquisition is a sweet spot for the company historically, it does not mean that the company won t look at bigger acquisitions. …


Pharma major Lupin targets $1 bn revenue from inorganic growth by FY18 #medical #sales #jobs

Posted On Nov 21 2016 by

#lupin pharma # Pharma major Lupin targets $1 bn revenue from inorganic growth by FY18 Sohini Das | Ahmedabad Jan 19, 2016 10:01 AM IST Looking to add $1 billion in revenues from inorganic growth to reach its target turnover of $5 billion by 2018, pharma giant Lupin, which is currently worth $2 billion, says it is open to late stage speciality assets. Lupin s chief financial officer Ramesh Swaminathan told Business Standard that while $200-300 million per acquisition is a sweet spot for the company historically, it does not mean that the company won t look at bigger acquisitions. …


Pharma major Lupin targets $1 bn revenue from inorganic growth by FY18 #pharma #conference

Posted On Nov 12 2016 by

#lupin pharma # Pharma major Lupin targets $1 bn revenue from inorganic growth by FY18 Sohini Das | Ahmedabad Jan 19, 2016 10:01 AM IST Looking to add $1 billion in revenues from inorganic growth to reach its target turnover of $5 billion by 2018, pharma giant Lupin, which is currently worth $2 billion, says it is open to late stage speciality assets. Lupin s chief financial officer Ramesh Swaminathan told Business Standard that while $200-300 million per acquisition is a sweet spot for the company historically, it does not mean that the company won t look at bigger acquisitions. …


Pharma major Lupin targets $1 bn revenue from inorganic growth by FY18 #marketing #pharmaceuticals

Posted On Nov 3 2016 by

#lupin pharma # Pharma major Lupin targets $1 bn revenue from inorganic growth by FY18 Sohini Das | Ahmedabad Jan 19, 2016 10:01 AM IST Looking to add $1 billion in revenues from inorganic growth to reach its target turnover of $5 billion by 2018, pharma giant Lupin, which is currently worth $2 billion, says it is open to late stage speciality assets. Lupin s chief financial officer Ramesh Swaminathan told Business Standard that while $200-300 million per acquisition is a sweet spot for the company historically, it does not mean that the company won t look at bigger acquisitions. …


Pharma major Lupin targets $1 bn revenue from inorganic growth by FY18

Posted On Sep 27 2016 by

#lupin pharma # Pharma major Lupin targets $1 bn revenue from inorganic growth by FY18 Sohini Das | Ahmedabad Jan 19, 2016 10:01 AM IST Looking to add $1 billion in revenues from inorganic growth to reach its target turnover of $5 billion by 2018, pharma giant Lupin, which is currently worth $2 billion, says it is open to late stage speciality assets. Lupin s chief financial officer Ramesh Swaminathan told Business Standard that while $200-300 million per acquisition is a sweet spot for the company historically, it does not mean that the company won t look at bigger acquisitions. …